phenytoin has been researched along with Psychoses, Drug in 32 studies
Excerpt | Relevance | Reference |
---|---|---|
" The case of a nonepileptic patient who developed psychosis following phenytoin treatment for trigeminal neuralgia is described." | 3.72 | Acute psychosis due to treatment with phenytoin in a nonepileptic patient. ( Angelopoulos, E; Gatzonis, SD; Mantouvalos, V; Ploumbidis, D; Sarigiannis, P; Siafakas, A, 2003) |
"A 21-year-old white man, with propionic acidemia and seizures treated with phenytoin and carbamazepine, was started on isradipine for essential hypertension." | 3.71 | Phenytoin/isradipine interaction causing severe neurologic toxicity. ( Cachat, F; Tufro, A, 2002) |
"Decreased libido and impotence were more common in patients given primidone." | 2.66 | Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. ( Browne, TR; Collins, JF; Cramer, JA; Delgado-Escueta, AV; Mattson, RH; McCutchen, CB; McNamara, JO; Smith, DB; Treiman, DM; Williamson, PD, 1985) |
"32 patients with Sydenham's chorea were studied at the La Rabida Institute for psychometric performance on the Minnesota Multiphasic Personality Inventory (MMPI)." | 1.27 | Chronic dopaminergic sensitivity after Sydenham's chorea. ( Bacon, LD; Bieliauskas, LA; Glantz, RN; Hagerty, M; Koller, WC; Nausieda, PA, 1983) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 25 (78.13) | 18.7374 |
1990's | 3 (9.38) | 18.2507 |
2000's | 3 (9.38) | 29.6817 |
2010's | 1 (3.13) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Shimura, M | 1 |
Yamada, H | 1 |
Takahashi, H | 1 |
Yamada, N | 1 |
Go, S | 1 |
Yamanaka, G | 1 |
Kawashima, H | 1 |
Cachat, F | 1 |
Tufro, A | 1 |
MOLING, JH | 1 |
POSCH, JJ | 1 |
Gatzonis, SD | 1 |
Angelopoulos, E | 1 |
Sarigiannis, P | 1 |
Mantouvalos, V | 1 |
Ploumbidis, D | 1 |
Siafakas, A | 1 |
Cvetko, B | 1 |
Dahl, JR | 1 |
Nausieda, PA | 1 |
Bieliauskas, LA | 1 |
Bacon, LD | 1 |
Hagerty, M | 1 |
Koller, WC | 1 |
Glantz, RN | 1 |
Reynolds, EH | 2 |
Surman, OS | 1 |
Parker, SW | 1 |
Tsuji, M | 1 |
Hori, S | 1 |
Asai, N | 1 |
Hamanaka, T | 1 |
Ishikawa, T | 1 |
Hiyoshi, T | 1 |
Mochizuki, H | 1 |
Kanemoto, K | 1 |
Miyamoto, T | 1 |
Kawasaki, J | 1 |
Freed, ED | 1 |
Stores, G | 1 |
Franks, RD | 1 |
Richter, AJ | 1 |
Gill, MA | 1 |
Kern, JW | 1 |
Kaneko, J | 1 |
McKeon, J | 1 |
Davis, C | 1 |
Trimble, MR | 1 |
Efabumuyi, OI | 1 |
Jefries, JJ | 1 |
Herberg, KP | 1 |
McDanal, CE | 1 |
Bolman, WM | 1 |
Mark, VH | 1 |
Zbinden, G | 1 |
Sultan, S | 1 |
Chouinard, G | 1 |
Beaudry, P | 1 |
Kugoh, T | 1 |
Inoue, T | 1 |
Utsumi, T | 1 |
Hamada, T | 1 |
Hosokawa, K | 1 |
Lepore, V | 1 |
Di Reda, N | 1 |
Defazio, G | 1 |
Pedone, D | 1 |
Giovine, A | 1 |
Lanzi, C | 1 |
Tartaglione, B | 1 |
Livrea, P | 1 |
Miller, WI | 1 |
Bhatia, MS | 1 |
Singhal, PK | 1 |
Kaur, N | 1 |
Gallitto, G | 1 |
Bramanti, P | 1 |
Di Rosa, AE | 1 |
Musolino, R | 1 |
De Domenico, P | 1 |
Troilo, G | 1 |
Santoro, M | 1 |
Di Perri, R | 1 |
Mattson, RH | 1 |
Cramer, JA | 1 |
Collins, JF | 1 |
Smith, DB | 1 |
Delgado-Escueta, AV | 1 |
Browne, TR | 1 |
Williamson, PD | 1 |
Treiman, DM | 1 |
McNamara, JO | 1 |
McCutchen, CB | 1 |
Gibberd, FB | 1 |
Fahn, S | 1 |
Craddock, G | 1 |
Kumin, G | 1 |
Andreasen, PB | 1 |
Heshe, J | 1 |
Patel, H | 1 |
Crichton, JU | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
An Open Prospective Randomised Long-Term Effectiveness Study, Comparing Best Medical Practice With or Without Adjunctive VNS Therapy in Patients 16 Years and Older With Pharmaco-resistant Partial Epilepsy[NCT00522418] | Phase 4 | 122 participants (Actual) | Interventional | 2006-02-28 | Terminated (stopped due to Insufficient enrollment) | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Adverse Events Profile (AEP) is a 19-item scale used as a systematic measure of adverse effects from antiepileptic drugs (AEDs). Scores range from 19-76; higher scores indicate high prevelance and severity of adverse events. (NCT00522418)
Timeframe: Mean change from baseline AEP Score at 12 months
Intervention | Units on a scale (Mean) |
---|---|
VNS Therapy | -6.0 |
Best Medical Practice | -3.2 |
The Center for Epidemiologic Studies Depression Scale (CES-D) includes 20 items comprising six scales reflecting major dimensions of depression: depressed mood, feelings of guilt and worthlessness, feelings of helplessness and hopelessness, psychomotor retardation, loss of appetite, and sleep disturbance. Possible range of scores is 0 to 60, higher scores indicate more depressive symptoms. (NCT00522418)
Timeframe: Mean change from baseline CES-D Score at 12 months
Intervention | Units on a Scale (Mean) |
---|---|
VNS Therapy | -2.2 |
Best Medical Practice | 0.5 |
The Neurological Disorders Depression Inventory for Epilepsy (NDDI-E) is a 6-item questionnaire validated to screen for depression in people with epilepsy. Scores range from 6 to 24, with higher scores indicating more depressive symptoms. (NCT00522418)
Timeframe: Mean change from baseline NDDI-E Score at 12 months
Intervention | Units on a Scale (Mean) |
---|---|
VNS Therapy | -1.0 |
Best Medical Practice | -0.2 |
Change from baseline in number of AED medications by visit (NCT00522418)
Timeframe: Change from baseline in number of AEDs at 12 months
Intervention | Number of AEDs Taken (Median) |
---|---|
VNS Therapy | 0 |
Best Medical Practice | 0 |
The Clinical Global Impression scale (CGI-I) is a 7 point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention Scores range from 1-7: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. (NCT00522418)
Timeframe: Mean change from baseline CGI-I Score at 12 months
Intervention | Units on a Scale (Mean) |
---|---|
VNS Therapy | -0.8 |
Best Medical Practice | -0.3 |
Percent change in total seizuires per week from baseline at 12 months (NCT00522418)
Timeframe: Mean percent change from baseline in seizure frequency at 12 months
Intervention | Percent Change (Mean) |
---|---|
VNS Therapy | -19.1 |
Best Medical Practice | -1.0 |
QOLIE-89 contains 17 multi-item measures of overall quality of life, emotional well-being, role limitations due to emotional problems, social support, social isolation, energy/fatigue, worry about seizure, medication effects, health discouragement, work/driving/social function, attention/concentration, language, memory, physical function, pain, role limitations due to physical problems, and health perceptions. Range of values 0-100. Higher scores reflect better quality of life; lower ones, worse quality of life. (NCT00522418)
Timeframe: Mean change from baseline QOLIE-89 Overall Score at 12 months
Intervention | units on a scale (Mean) |
---|---|
VNS Therapy | 5.5 |
Best Medical Practice | 1.2 |
Response Rate is defined as the percent of participants who are responders. A Responder is defined as participants with a reduction of at least 50% or 75% in seizure frequency from baseline to the seizure count evaluation period. (NCT00522418)
Timeframe: Number of Responders at 12 Months
Intervention | participants (Number) |
---|---|
VNS Therapy | 10 |
Best Medical Practice | 7 |
QOLIE-89 contains 17 multi-item measures of overall quality of life. Range of values 0-100. Higher scores reflect better quality of life; lower ones, worse quality of life. Adverse Events Profile (AEP) is a 19-item scale used as a systematic measure of adverse effects from antiepileptic drugs (AEDs). Scores range from 19-76; higher scores indicate high prevelance and severity of adverse events. (NCT00522418)
Timeframe: Change from baseline up to 12 months
Intervention | units on a scale (Least Squares Mean) | |
---|---|---|
VNS Therapy | Best Medical Practice | |
Baseline Adverse Event Profile Score < 40 | 3.3 | 0.5 |
QOLIE-89 contains 17 multi-item measures of overall quality of life. Range of values 0-100. Higher scores reflect better quality of life; lower ones, worse quality of life. Adverse Events Profile (AEP) is a 19-item scale used as a systematic measure of adverse effects from antiepileptic drugs (AEDs). Scores range from 19-76; higher scores indicate high prevelance and severity of adverse events. (NCT00522418)
Timeframe: Change from baseline up to 12 months
Intervention | Units on a Scale (Least Squares Mean) | |
---|---|---|
VNS Therapy | Best Medical Practice | |
Baseline Adverse Event Profile Score >= 40 | 3.3 | 0.7 |
2 reviews available for phenytoin and Psychoses, Drug
Article | Year |
---|---|
Mental effects of antiepileptic medication: a review.
Topics: Adolescent; Adult; Anticonvulsants; Attention; Barbiturates; Brain Chemistry; Carbamazepine; Child; | 1983 |
Behavioural effects of anti-epileptic drugs.
Topics: Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Carbamazepine; Confusion; Disorders of Excess | 1975 |
1 trial available for phenytoin and Psychoses, Drug
Article | Year |
---|---|
Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures.
Topics: Adolescent; Adult; Aged; Carbamazepine; Clinical Trials as Topic; Double-Blind Method; Epilepsies, P | 1985 |
29 other studies available for phenytoin and Psychoses, Drug
Article | Year |
---|---|
Antiepileptic drug-induced psychosis associated with MTHFR C677T: a case report.
Topics: Adolescent; Anticonvulsants; Avitaminosis; Epilepsy; Humans; Male; Methylenetetrahydrofolate Reducta | 2019 |
Phenytoin/isradipine interaction causing severe neurologic toxicity.
Topics: Acidosis; Adult; Anticonvulsants; Antihypertensive Agents; Calcium Channel Blockers; Drug Interactio | 2002 |
Acute diphenylhydantoin intoxication: report of two cases.
Topics: Drug-Related Side Effects and Adverse Reactions; Humans; Hydantoins; Phenytoin; Psychoses, Substance | 1957 |
Acute psychosis due to treatment with phenytoin in a nonepileptic patient.
Topics: Anticonvulsants; Female; Humans; Middle Aged; Phenytoin; Psychoses, Substance-Induced; Trigeminal Ne | 2003 |
[Intolerance syndrome in diphenylhydantoin therapy].
Topics: Cerebellum; Drug Hypersensitivity; Electroencephalography; Humans; Male; Phenytoin; Psychoses, Subst | 1966 |
Diphenylhydantoin toxic psychosis with associated hyperglycemia.
Topics: Glycosuria; Humans; Hyperglycemia; Male; Middle Aged; Phenytoin; Psychoses, Substance-Induced | 1967 |
Chronic dopaminergic sensitivity after Sydenham's chorea.
Topics: Adult; Amphetamines; Appetite Depressants; Chorea; Contraceptives, Oral; Dopamine; Female; Humans; M | 1983 |
Complex partial seizures and psychiatric disturbance in end-stage renal disease.
Topics: Acute Kidney Injury; Adult; Anticonvulsants; Electroencephalography; Female; Humans; Methyldopa; Phe | 1981 |
Two epileptics showing antiepileptic drug-induced psychoses.
Topics: Adolescent; Anticonvulsants; Dose-Response Relationship, Drug; Drug Therapy, Combination; Electroenc | 1993 |
Running down phenomenon and acute interictal psychosis in medial temporal lobe epilepsy.
Topics: Adult; Age Factors; Anticonvulsants; Epilepsy, Temporal Lobe; Female; Humans; Isoxazoles; Male; Phen | 2000 |
The drug management of acute behavioural disturbances.
Topics: Acting Out; Acute Disease; Adrenergic beta-Antagonists; Aged; Antidepressive Agents, Tricyclic; Anti | 1975 |
Schizophrenia-like psychosis associated with anticonvulsant toxicity.
Topics: Adult; Anticonvulsants; Athetosis; Carbamazepine; Chorea; Dose-Response Relationship, Drug; Drug The | 1979 |
Phenytoin overdose. Kinetics.
Topics: Humans; Kinetics; Male; Middle Aged; Phenytoin; Psychoses, Substance-Induced | 1978 |
Anticonvulsant drugs and mental symptoms: a review.
Topics: Anticonvulsants; Carbamazepine; Dose-Response Relationship, Drug; Epilepsy; Ethosuximide; Folic Acid | 1976 |
Treatment of drug-induced psychosis with diphenylhydantoin.
Topics: Adult; Cognition Disorders; Female; Hallucinations; Hallucinogens; Humans; Illusions; Male; Phenytoi | 1976 |
Delayed and insidious onset of diphenylhydantoin toxicity.
Topics: Adolescent; Adult; Animals; Cerebellar Ataxia; Drug Interactions; Electroencephalography; Epilepsy; | 1975 |
Delayed idiosyncratic psychosis with diphenylhydantoin.
Topics: Adult; Epilepsy; Female; Humans; Paranoid Disorders; Phenytoin; Psychoses, Substance-Induced; Time F | 1975 |
Letter: Delayed idiosyncratic psychosis with phenytoin.
Topics: Humans; Phenytoin; Psychoses, Substance-Induced | 1975 |
[Dangers of drug combinations (author's transl)].
Topics: Anticoagulants; Barbiturates; Contraceptives, Oral, Hormonal; Drug Antagonism; Drug Interactions; Dr | 1976 |
Antiepileptic drugs in the treatment of neuroleptic-induced supersensitivity psychosis.
Topics: Adult; Antipsychotic Agents; Carbamazepine; Female; Humans; Male; Middle Aged; Phenytoin; Psychoses, | 1990 |
Five epileptic cases who manifested psychotic states under the toxic levels of antiepileptic drugs.
Topics: Anticonvulsants; Dose-Response Relationship, Drug; Drug Therapy, Combination; Epilepsy; Humans; Phen | 1990 |
Dopaminomimetic action of diphenylhydantoin in rat striatum: effect on homovanillic acid and cyclic AMP levels.
Topics: Animals; Apomorphine; Corpus Striatum; Cyclic AMP; Dyskinesia, Drug-Induced; Haloperidol; Homovanill | 1985 |
Phenytoin chronic toxicity and associated psychosis.
Topics: Aged; Chronic Disease; Female; Humans; Phenytoin; Psychoses, Substance-Induced | 1988 |
Psychosis associated with anticonvulsant toxicity.
Topics: Adolescent; Anticonvulsants; Carbamazepine; Child; Humans; Intellectual Disability; Male; Phenytoin; | 1987 |
Diphenylhydantoin encephalopathy. A case report.
Topics: Adult; Dose-Response Relationship, Drug; Electroencephalography; Epilepsies, Partial; Evoked Potenti | 1985 |
Epilepsy.
Topics: Adult; Child; Epilepsies, Partial; Epilepsy; Epilepsy, Absence; Epilepsy, Temporal Lobe; Epilepsy, T | 1969 |
Acute toxic psychosis from suicidal overdosage of amantadine.
Topics: Acute Disease; Amantadine; Blood-Brain Barrier; Chlorpromazine; Humans; Male; Middle Aged; Parkinson | 1971 |
[Neuropsychiatric manifestations of systemic lupus erythematosus].
Topics: Adult; Chlorpromazine; Chlorprothixene; Female; Humans; Lupus Erythematosus, Systemic; Neurologic Ma | 1969 |
The neurologic hazards of diphenylhydantoin in childhood.
Topics: Adolescent; Ataxia; Child; Child, Preschool; Epilepsy; Female; Humans; Infant; Male; Neurologic Mani | 1968 |